CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Oncolinx has developed a targeted cancer treatment using antibody-drug conjugates that deliver a potent drug specifically to malignant cells, minimizing damage to healthy tissue. This innovative approach aims to effectively treat drug-resistant cancers and activate the immune response.
Oncolinx has developed a novel molecular platform allowing for non-invasive and highly effective cancer cures.
The platform carries a killing drug (Azonafide), linked to an antibody, specifically targeting and destroying only malignant tumour cells.
These molecular complexes are called Antibody Drug Conjugates (ADCs) and represent a strong, valid alternative to current chemotherapies.
Oncolinx’s innovative linker/payload technology enables the Azonafide platform to perform a sensitive discrimina…
ONCOLINX UK LIMITED
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
